Showing 1881-1890 of 3223 results for "".
- Altris Launches New Artificial Intelligence Platform for Automated OCT Scanshttps://modernod.com/news/altris-launches-new-artificial-intelligence-platform-for-automated-oct-scans/2481202/Altris Inc. announced the launch of Altris AI, an artificial-intelligence-powered software platform designed to automate OCT examination. The secure, cloud-based platform provides fast analysis and visualization of 100 pathologies and pathological signs, including rare ones, according to Altris.<
- Alcon to Celebrate 75 Years and Showcase Contact Lens Innovations at #Academy22https://modernod.com/news/alcon-to-celebrate-75-years-and-showcase-contact-lens-innovations-at-academy22/2481197/Alcon will feature a host of innovations across its portfolio of products along with pertinent practice takeaways at the American Academy of Optometry Annual Meeting (#Academy22) in San Diego, California, on October 27, 2022. The meeting coincides with Alcon’s Diamond Jubilee, celebrating 7
- Moria Expands its Footprint into Eye Surgery by Acquiring Alchimia SRLhttps://modernod.com/news/moria-expands-its-footprint-into-eye-surgery-by-acquiring-alchimia-srl/2481161/France-based Moria has announced the acquisition of Italian-based company Alchimia SRL, a manufacturer of devices for ophthalmic surgery and human tissue banking. Financial terms of the deal were not disclosed. Founded in 1993, Alchimia has 30 years of expertis
- Santen Announces Health Canada Approval for Cationorm Plus to Relieve the Symptoms of Dry Eye and Ocular Allergyhttps://modernod.com/news/santen-announces-health-canada-approval-for-cationorm-plus-to-relieve-the-symptoms-of-dry-eye-and-ocular-allergy/2481160/Santen Canada announced the approval of Cationorm Plus by Health Canada. Cationorm Plus is a hydrating artificial tear that restores moisture in the eye to provide long-lasting relief for dry eye and ocular allergy symptoms. “Millions of Canadians are impacted by the dis
- Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathyhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-part-1-of-phase-3-guard-trial-of-adx-2191-in-proliferative-vitreoretinopathy/2481155/Aldeyra Therapeutics announced the achievement of the primary endpoint in Part 1 of the phase 3 GUARD Trial of ADX-2191 (methotrexate injection, USP1) for intravitreal administration, an investigational drug candidate, for the prevention of proliferative vitreoretinopathy (PVR). ADX-21
- New Study Shows People with Glaucoma are at Significant Risk of Alzheimer’s Diseasehttps://modernod.com/news/new-study-shows-people-with-glaucoma-are-at-significant-risk-of-alzheimers-disease/2481142/A large, nationwide study from Taiwan shows that people with a specific type of glaucoma, called normal-tension glaucoma, are at high risk for developing Alzheimer&r
- Alcon Introduces Clareon Toric IOL Featuring Stableforce Haptics Technologyhttps://modernod.com/news/alcon-completes-availability-of-clareon-portfolio-with-clareon-toric-during-aao-2022/2481134/Alcon announced new product launches in the US as well as
- Santen and UBE Receive FDA Approval for Omlonti for the Reduction of Elevated IOP in Patients with Primary Open-Angle Glaucoma or Ocular Hypertensionhttps://modernod.com/news/santen-and-ube-receive-fda-approval-for-omlonti-for-the-reduction-of-elevated-iop-in-patients-with-primary-open-angle-glaucoma-or-ocular-hypertension/2481115/Santen and UBE announced that the FDA has approved Omlonti (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. Omi
- Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Networkhttps://modernod.com/news/alimera-announces-agreement-with-jaeb-center-for-health-research-on-behalf-of-the-drcr-retina-network/2481112/Alimera Sciences announced that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network, to support and provide Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Irelandhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-ireland/2481105/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segme